SCHEMBL4774817

SCHEMBL4774817

Cc1c[nH]c(CCNc2cc(-c3cccnc3)nc(-c3ccccn3)n2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.46
CYP2C9 P11712 3/20 0.46
PTGDR Q13258 3/20 0.44
CYP2A6 P11509 1/20 0.41
CYP1A2 P05177 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
USP2 O75604 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SLC2A1 P11166 1/20 0.40
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HDAC1 Q13547 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237967 0.85 CYP3A4 (0.47) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2
SCHEMBL4773623 0.82 CYP3A4 (0.48) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2
SCHEMBL2240945 0.81 GBA1 (0.54) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2
SCHEMBL2238098 0.81 PTGDR (0.53) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2
SCHEMBL4775037 0.81 EGFR (0.42) CYP3A4CYP2C9PTGDRCYP2A6HSD17B10
SCHEMBL4773528 0.80 PTGDR (0.43) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2
SCHEMBL2239349 0.80 CDK4 (0.47) CYP3A4CYP2C9PTGDRCYP1A2CLK4
SCHEMBL2241055 0.80 CYP3A4 (0.51) CYP3A4CYP2C9PTGDRCYP1A2CLK4
SCHEMBL2241071 0.80 CYP3A4 (0.57) CYP3A4CYP2C9CYP1A2CLK4USP2
SCHEMBL2238664 0.80 CYP3A4 (0.47) CYP3A4CYP2C9PTGDRCYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed